Treatlink
treatlink is a healthtech company focused on uncovering individual bio-signatures of Glioblastoma tumors through genetic, epigenetic, transcriptomic, and metabolic markers to understand tumor reactions to treatment.
Classification
Profile
Funding
Funding details not yet available.
Links patients to their best treatment by uncovering individual bio-signatures of Glioblastoma tumors through genetic, epigenetic, transcriptomic, and metabolic markers.
Patients with Glioblastoma and potentially healthcare providers seeking personalized treatment strategies for this aggressive primary brain tumor.
- Service fees - per-sample multi-omics analysis + AI interpretation
Direct sales force (scientific liaison) targeting pharma R&D leads and hospital trial coordinators · Strategic partnerships with university hospitals (data-sharing agreements) and CROs · Industry conferences & webinars (e.g., ESMO, AACR) to showcase case studies and AI demos
Michael Rauch provides financial and entrepreneurial expertise, leveraging experience as CFO & CEO for publicly-traded and PE-owned multinationals.
R&D costs associated with multi-omics analysis and artificial intelligence development for tumor characterization.
Proprietary technology to uncover individual bio-signatures and a leadership team with healthtech and multinational corporate experience.
Analyzing unique tumor patterns via genetic, epigenetic, transcriptomic, and metabolic markers to understand Glioblastoma and treatment reactions.
Long-term partnership contracts (multi-year service-level agreements) with pharma and CROs · Dedicated account managers for each partner to co-design study protocols · Consulting-driven onboarding - workshops, training modules, and continuous support
Competes in the healthtech sector addressing Glioblastoma, a disease with only 12-15 months median survival despite standard care.
Glioblastoma is the most aggressive primary brain tumor with poor survival rates; standard of care has remained unchanged for decades.
- Diversify Revenue Beyond Services
What is the current pricing structure for per-sample analysis and SaaS licensing? · Does Treatlink already have signed contracts with pharma or CRO partners, or are they still in prospecting mode? · Are there geographic expansion plans (e.g., EU vs. US market) that would affect partnership and regulatory strategies?
Value ↔ Revenue - The AI-driven stratification directly enables premium SaaS licensing and per-sample fees · Key Resources ↔ Key Activities - Proprietary AI models and biobank are the engines that power the multi-omics analysis workflow · Customer Segments ↔ Channels - Pharma partners are reached via direct sales and CRO alliances; hospitals via re
- The company’s membership in BIO Deutschland and recent public filing (HRB 756014) confirm a legally established German biotech entity[1]
No investors recorded yet.